Skip to main content
. 2009 Jul 6;2009:187015. doi: 10.1155/2009/187015

Table 2.

Effect of FR-91 on peripheral blood mononuclear cell (PBMC) subsets from NHL patients.

CD3/control CD3/FR-91 10 μg/mL CD3/FR-91 25 μg/mL
X* 57.73 71.09 69.45
SD** 3.97 4.67 6.72
CV*** 0.06 0.06 0.09
P**** .001 .002

HLA-DR/control HLA-DR/FR-91 10 μg/mL HLA-DR/FR-91 25 μg/mL
X 8.5 5.66 6.36
SD 2.08 2.18 4.16
CV 0.24 0.38 0.65
P .002 .109

CD4/control CD4/FR-91 10 μg/mL CD4/FR-91 25 μg/mL
X 36.28 48.39 47.41
SD 8.6 6.27 4.95
CV 0.23 0.13 0.1
P .001 .002

CD25/control CD25/FR-91 10 μg/mL CD25/FR-91 25 μg/mL
X 6.12 5.62 5.47
SD 4.34 3.84 2.51
CV 0.7 0.68 0.46
P .32 .41

CD8/control CD8/FR-91 10 μg/mL CD8/FR-91 25 μg/mL
X 26.96 23.47 23.96
SD 7.52 4.22 3.58
CV 0.27 0.17 0.15
P .17 .11

CD69/control CD69/FR-91 10 μg/mL CD69/FR-91 25 μg/mL
X 22.37 12.83 13.33
SD 9.63 4.06 4.31
CV 0.43 0.31 0.32
P .01 .008

n = 15; *mean; **standard deviation; ***coefficient of variation; **** <.05: significant values.